Rucaparib in Patients with Metastatic Castration-resistant Prosta

Primary Objective: • To assess the efficacy of rucaparib based on the response rate in mCRPC patients with HRD who progressed on AR-targeted therapy (abiraterone acetate, enzalutamide, or investigational AR-targeted agent) and taxane-based chemotherapy in the castrationresistant setting

July 03, 2017